GlobeImmune

GlobeImmune is a biopharmaceutical company located in Louisville, Colorado. Founded in 1995, the company employs 14 people and generates revenue exceeding $10,000. GlobeImmune specializes in developing treatments for cancer and infectious diseases using its proprietary Tarmogen ® platform. The Tarmogen ® platform stimulates a specific subset of white blood cells called T cells, which destroy infected or malignant cells. This approach differs from traditional vaccines, which primarily stimulate antibody production. GlobeImmune's technology targets the molecular profile of diseased cells, aiming to develop a broad portfolio of products for a range of medical needs. Currently, GlobeImmune has four Tarmogen product candidates undergoing clinical evaluation for both infectious diseases and various cancer indications. The company actively collaborates with other biopharmaceutical companies and research institutions to advance the development of these product candidates while managing its research and development expenses. GlobeImmune maintains a strong web presence, with its website accessible at globeimmune.com.